Delaunay Boris, Soh Patrice Njomnang, Delannes Martine, Riou Olivier, Malavaud Bernard, Moreno Ferran, Craven Jordi, Soulie Michel, Huyghe Eric
Department of Urology, Andrology and Sexology, Toulouse Rangueil University Hospital, Toulouse, France.
Department of Radiotherapy, Claudius Regaud Cancer Center, Toulouse, France.
Brachytherapy. 2014 Jul-Aug;13(4):380-7. doi: 10.1016/j.brachy.2013.06.001. Epub 2013 Jul 26.
Penis brachytherapy (PB) remains an alternative in the cancer treatment. The objective of this study was to assess the oncologic outcomes, sexual function, and the sexual behavior of men treated by PB for a cancer of the penis.
Between 1992 and 2009, 47 patients with a cancer of the penis were treated by PB ((192)Ir), in the Toulouse, Montpellier, and Barcelona cancer centers. The investigation into their sexuality was obtained by means of questionnaire. A total of 21 French patients were approached, of whom 19 (mean age=73.2 years) agreed to answer the questionnaire (participation rate=90.5%).
Oncologic data: The specific survival and the disease-free survival at 5 years was 87.6% (95% confidence interval, 72.4-94.7%) and 84% (95% confidence interval, 57.6-94.7%), respectively. The rate of preservation of the penis was 66% (n=31). Sexual data: Among the 17 patients sexually active before brachytherapy, 10 patients remained sexually active after treatment (58.8%). Of the 18 patients who had erections before PB, 17 still had them after treatment (94.4%). Age was the main predictive factor.
The PB seems to have a moderated impact on the sexual functions and the sexual behavior of the patients.
阴茎近距离放射治疗(PB)仍是癌症治疗的一种选择。本研究的目的是评估接受PB治疗阴茎癌的男性的肿瘤学结局、性功能和性行为。
1992年至2009年间,图卢兹、蒙彼利埃和巴塞罗那癌症中心对47例阴茎癌患者进行了PB(铱-192)治疗。通过问卷调查对他们的性行为进行调查。共联系了21名法国患者,其中19名(平均年龄=73.2岁)同意回答问卷(参与率=90.5%)。
肿瘤学数据:5年时的特异性生存率和无病生存率分别为87.6%(95%置信区间,72.4-94.7%)和84%(95%置信区间,57.6-94.7%)。阴茎保留率为66%(n=31)。性数据:在近距离放射治疗前有性行为的17名患者中,10名患者治疗后仍有性行为(58.8%)。在接受PB治疗前有勃起功能的18名患者中,17名患者治疗后仍有勃起功能(94.4%)。年龄是主要的预测因素。
PB似乎对患者的性功能和性行为有适度影响。